Why should I pay attention for treatment compliance in patients with acute coronary syndrome?

Current data obtained from antiplatetelet studies performed in patients with acute coronary syndrome demonstrate that antiplatelet resistance is associated with increased risk for stent thrombosis and other ischemic events whereas overinhibition increases the bleeding risk. Individualized treatment algorithms in this setting should be based on clearly defined treatment windows in which benefits and risks are well-balanced.